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Abstract
Introduction Patients in the intensive care unit (ICU) may be in
an inadequate condition to give their informed consent for
research. The aim of this study was to analyse the ability to recall
participation in a clinical trial for which ICU patients had given
their consent.
Methods The data presented are a two-step observational
study: first, a protocolled informed consent procedure was
conducted then the informed consent was given by the patient,
and second, a patient interview was held 10 ± 2 days later by
the same investigator. The primary endpoints were the ability to
recall their participation in the clinical trial, as well as its purpose
and related risks. As secondary endpoints, we investigated
whether asking questions about the clinical trial or reading the
informative leaflet was related to the recall. To be included in the
study, the patient had to have a Glasgow Coma Scale score of
15, be fully oriented and free of mechanical ventilation, and be
judged competent by both the investigator and the attending
physician. Patients admitted to the ICU after major surgery or
trauma were eligible. However, patients who refused to
participate, or those whose next-of-kin gave consent, were
excluded.
Results Of the 44 patients, 35 (80%) recognized, 10 to 12 days
after informed consent had been obtained, that they had
participated in the clinical trial, but only 14 out of 44 (32%)
could recall the clinical trial purpose and its related risks. More
patients with complete recall had read the informative leaflet or
asked at least one question before signing the informed
consent. Asking at least one question was associated with
complete recall.
Conclusion Our results confirm that obtaining informed consent
for research during an ICU stay is associated with poor patient
recall of participation in a clinical trial and its components
(purpose and risk). Whether encouraging reading the
informative leaflet and asking questions about the clinical trial
improves the informed consent procedure remains to be fully
investigated.
Introduction
Within the past few decades, medicine, especially critical care
medicine, has progressed spectacularly as a result of medical
research and the participation of patients in clinical trials. The
Declaration of Helsinki and international guidelines require
that the patient give informed consent before participating in a
study. This informed consent is essential to respect the auton-
omy of patients and protect them against abuse [1-3].
Therefore, to respect the ethical principles of clinical research,
informed consent for research demands to be held at a high
standard because the patient does not always benefit directly
from the research results and might suffer some risks for the
good of the community. Keeping with this high standard,
informed consent must fulfil three mandatory conditions as
described in the Belmont report: adequate information about
the study with a complete disclosure of the risks and benefits,
the patient's comprehension, and the voluntariness [4-7]. This
means that the patient should be able to freely decide their
participation in the study without any external pressure and
that they could resign from the study at any time without any
consequence to their care. To respect this requirement and
the principle of autonomy, it is essential that patients compre-
hend and recall knowledge of the study components as well
GCS = Glasgow Coma Scale; ICU = intensive care unit.Critical Care    Vol 10 No 6    Chenaud et al.
Page 2 of 8
(page number not for citation purposes)
as their participation in the study. However, patients in the
intensive care unit (ICU) may be in an inadequate condition to
give their informed consent for a research study because their
capacity for comprehension is questionable. However, lighter
sedation of ICU patients permits an increasing number of them
to remain conscious. These patients seem to be able to under-
stand the information presented and to decide freely if they
would like to participate in the study. However, there is no
available consensus on the capacity required to give consent
[8]. As objective criteria regarding the decision-making capac-
ity of patients are lacking in international and national direc-
tives, investigators usually use their clinical judgement and the
Glasgow Coma Scale (GCS) as guidance. Previously, we
showed that 22% of clinical trial participants could not recall
their participation in the clinical trial despite the fact that
informed consent was obtained in an ideal situation, namely
before their admission to the ICU [9]. Furthermore, 25% of
patients were unable to recall the clinical trial purpose and its
related risks. In view of these results, we hypothesized that
informed consent for research obtained from a patient during
their ICU stay is associated with an even worse ability for them
to recall their participation in a clinical trial and its components
(purpose and risk).
Materials and methods
Design
This investigation on informed consent was an observational
substudy of a clinical trial about inflammation, described else-
where [10]. The present study was designed in two steps:
first, a protocolled informed consent procedure was con-
ducted then the informed consent was given by the patient,
and second, a patient interview was held 10 ± 2 days later by
the same investigator about their participation, the purpose,
and the risks related to the clinical trial on inflammation.
Setting
This study was performed in a 20-bed surgical ICU of a terti-
ary-university-affiliated teaching hospital receiving 1,600
patients per year.
Type of participants
Patients admitted to the ICU after a major surgery or trauma
were eligible. To give their consent to participate in the clinical
trial on inflammation, patients had to present with a GCS
score of 15, be fully oriented and free of mechanical ventila-
tion, and judged competent by both the investigator and the
attending physician. Patients who refused to participate, met
any of the exclusion criteria for the clinical trial on inflammation,
and those whose next-of-kin gave consent were not consid-
ered for the present study. Furthermore, incompetent or non-
French-speaking patients, and those with psychiatric disor-
ders, senile dementia or other intellectual disabilities were not
included.
The informed consent procedure
A protocoled procedure detailing how to obtain informed con-
sent was developed to ensure that the two investigators con-
tributing to the study obtained consent in an identical manner.
The investigators were physicians who were not caring for the
patients enrolled in the study. Informed consent was obtained
on the ICU admittance date, after a 20-minute individual oral
presentation. During this presentation, the investigator
explained the clinical trial on inflammation, emphasizing two
clinical trial components: the purpose and its related risks. The
defined keyword for the clinical trial purpose was inflammation.
The clinical trial risk for the patient was that 10 ml of their blood
would be drawn daily for the first five days of their ICU stay,
and a final blood draw would be required at day 28. The inves-
tigator told the patient that the risk was minimal.
The patient then received a one-page informative leaflet. At the
end of this procedure, the investigator asked the patient if he
had any questions about the clinical trial before signing the
informed consent form. The investigator noted whether the
patient asked any questions and/or if he read the informative
leaflet in his presence. These two attitudes of the patient (ask-
ing one or more questions and reading the informative leaflet)
were defined a priori in the consent procedure. No other atti-
tudes of the patient were recorded or tested.
This informed consent procedure conforms to recommenda-
tions on the ethical conduct of clinical research involving
patients in the ICU [11].
Data collection
Patient age, gender, history of daily alcohol intake type of
admission and diagnosis, as well as Simplified Acute Physio-
logical Score second version (SAPS II) [12] were recorded on
admission to the ICU. The lengths of mechanical ventilation
and ICU stay were also noted.
When informed consent was obtained, clinical and laboratory
values, the Sequential Organ Failure Assessment (SOFA)
score [13], and medical treatment given within the 24 hours
before and after the consent procedure were assessed.
At 10 ± 2 days (range), the investigator met the patient to plan
the blood sampling to be performed on day 28. At this time,
the investigator assessed whether the patient could recall par-
ticipation in the clinical trial and/or any of the clinical trial
components.
The primary endpoints were the ability of the patient to recall
participation in the clinical trial, as well as the purpose and
related risks of the clinical trial. As secondary endpoints, we
investigated whether asking questions about the clinical trial
or reading the informative leaflet was related to the recall.Available online http://ccforum.com/content/10/6/R170
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Patients who could report their participation in the clinical trial
on inflammation, the clinical trial purpose and the related risks
were assigned to the 'complete recall' group. Patients lacking
one or more components were assigned to the 'incomplete
recall' group.
Ethical issue
The clinical trial on inflammation itself, as well as the informa-
tive leaflet and the consent form, were approved by the Ethical
Committee for Human Research of our institution. Specific
informed consent had not been sought for this study. The edu-
cational status of the patient, that was the sole data not avail-
able in the dataset of the clinical trial, was subsequently
retrieved from the administrative file.
Statistical analysis
StatView for Windows version 5.0.1 (SAS Institute Inc., Cary,
NC, USA) was used for statistical analysis. Patients were strat-
ified as having either complete or incomplete recall; these data
were compared separately by using a two-tailed Fisher's exact
test, an unpaired t test or a Mann–Whitney U test, as deemed
appropriate. We also assessed the sensitivity, specificity, the
positive predictive value, the negative predictive value and the
likelihood ratio of factors that were statistically significant on
the basis of the univariate analysis performed to predict com-
plete recall of the clinical trial. Odds ratios with 95% confi-
dence intervals were calculated to estimate the effect size of
risk factors associated with complete recall. All tests were
two-tailed; p < 0.05 was considered significant.
Results
Between May 2000 and January 2001 we included 48
patients, of whom four died during the ICU stay (Figure 1). We
therefore analysed the data on 44 patients who signed the
informed consent and were alive at 10 ± 2 days; at this time
all patients presented with a GCS score of 15, were fully ori-
ented and were judged competent by the investigator.
Of the 44 patients, 35 (80%) recognized they had participated
in a clinical trial; 14 of the 44 patients (32%) could recall their
clinical trial participation as well as the clinical trial compo-
nents, namely the clinical trial purpose and the related risk
(Figure 1). These 14 patients were assigned to the 'complete
recall' group.
Patients with complete recall did not differ from patients with
incomplete recall with regard to their demographic, educa-
tional, and admission characteristics (Table 1). The lengths of
mechanical ventilation and ICU stay were similar in both
groups.
When informed consent was obtained, the clinical and labora-
tory values of the patients did not differ between the two
groups (Table 2). The medications administered during the 24
hours before and after the informed consent were similar in the
two groups (Table 2). More patients with complete recall had
read the informative leaflet or had asked at least one question
before signing the informed consent (13 out of 14 (93%)
versus 18 out of 30 (60%); p = 0.03). Asking at least one
Figure 1
Distribution of the patients Distribution of the patients.Critical Care    Vol 10 No 6    Chenaud et al.
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question was associated with a complete recall of the clinical
trial (p = 0.03). The sensitivity, specificity, positive predictive
values, and negative predictive values of 'asking one question'
and 'reading the informative leaflet or asking one question' to
differentiate patients with complete recall from patients with
incomplete recall are shown in Table 3.
The first investigator included 15 (34%) patients in the clinical
trial during the first three months of the inclusion period, and
the second investigator added 29 (66%) patients during the
last six months. Patient characteristics, attitude during the
informed consent procedure, and rates of recall did not differ
significantly between investigators (Table 4).
Discussion
A great majority of ICU patients who had consented to partic-
ipate in a clinical trial during their ICU stay recalled their clinical
trial participation after 10 ± 2 days. Other studies, including
those on patients with acute myocardial infarction, have
reported clinical trial participation recall rates similar to ours
[14-16]. Our rate is also similar to the rate we found in a study
in which informed consent was obtained in an ideal situation,
namely before ICU admission [9].
Although this may seem very encouraging, only 32% of the
patients who gave consent during their ICU stay recalled clin-
ical trial components; this is in contrast to our 'ideal situation'
previous study in which 75% of patients had a complete recall
[9]. The low rate of complete recall in the present study could
be explained by the difficulty of some ICU patients to process
information given the stress of the acute phase and possibly
experiencing feelings of dependence and anguish [17]. Our
routine clinical evaluation might not detect this potential cog-
nitive defect [18]. The reasons why some patients are able to
recall whereas others cannot therefore remain unclear.
The severity of disease, the neurological status of the patients,
and the medications received in the ICU when informed con-
sent was obtained and during the 24 hours after the informed
consent procedure were similar in both groups of our patients.
Table 1
Demographic, anamnestic characteristics and intensive care unit data of the two groups of patients
Characteristic Complete 
recall
Incomplete 
recall
p
n 14 30
Demographic and educational data
Age, years (mean ± SD) 54 ± 22 54 ± 21 > 0.99b
Male/female, n 9/5 19/11 0.95c
Educational status
Up to junior high school, n (percentage) 6 (43) 11(37) 0.89d
Intermediate (college), n (percentage) 6 (43) 16 (53)
Academic level or more, n (percentage) 1 (7) 1 (3)
Not available, n (percentage) 1 (7) 2 (7)
Daily alcohol intake, n (percentage) 1 (7) 8 (27) 0.23c
ICU and hospital data
Admission diagnosis, n (percentage) 0.77c
Abdominal surgery, n (percentage) 7 (50) 10 (33)
Cardiovascular surgery, n (percentage) 3 (21.5) 8 (27)
Trauma, n (percentage) 3 (21.5) 9 (30)
Other, n (percentage) 1 (7) 3 (10)
Emergency admission/elective admission, n 7/7 16/14 > 0.99c
Admission SAPS II (mean ± SD) 16 ± 10 20 ± 9 0.24b
Length of mechanical ventilationa, hours (median (range)) 0 (0–15) 0 (0–64) 0.47e
Length of ICU stay, days (median (range)) 3 (2–9) 4 (2–25) 0.43e
ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score second version. In the complete recall group, patients able to mention their 
clinical trial participation and the two clinical trial components; in the incomplete recall group, patients were unable to mention their clinical trial 
participation or one of the clinical trial components. aNone of the patients were intubated at the time of the informed consent procedure; 
bStudent's t test; cFisher's exact test; dχ2 test; eMann–Whitney U test.Available online http://ccforum.com/content/10/6/R170
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Inadequate information disclosure to some patients that could
explain our results can reasonably be excluded because the
information procedure was well standardized. In contrast with
previous reports, we found that neither age nor educational
status influenced the ability to recall clinical trial components
[19,20]. This might reflect the fact that the information pre-
sented was not difficult to understand.
If the informed consent satisfies the three criteria specified by
international guidelines, the consent is deemed valid [1,2,21].
However, if the clinical trial has already begun and the patient
is unaware of the purpose, related risks, and their participation
in the clinical trial, they are obviously unable to decide mind-
fully whether to continue in the clinical trial or to withdraw from
it at any time. In this case, we might question the respect of the
participant's autonomy offered by the informed consent. This
leads us to view the informed consent as a process rather than
a simple procedure. The informed consent process requires,
to our mind, multiple conversations on several occasions while
the research is conducted.
We found simple but important factors associated with com-
plete recall of the clinical trial components. We tried to identify
factors that were easy to observe by an investigator such as
'asking questions' and 'reading the informative leaflet'. In our
previous study, we found that more patients who were able to
mention all clinical trial components had read the leaflet and
had asked at least one question. 'Asking questions' increased
the chance of recall in critically ill patients. We could speculate
inversely that asking no questions could increase the potential
for poor initial comprehension of the clinical trial components.
Our results are in line with Flory and Emanuel's findings [22],
which concluded that person-to-person interaction with
clinical trial participants may be the most effective way of
improving their understanding.
This finding revives the debate about informed consent for
research in the ICU. In the past, deferred consent [23] or waiv-
ing of consent for research in the emergency setting [24,25]
was considered acceptable in particular research situations.
Table 2
Data at the time of informed consent and the attitude of the patients
Parameter Complete recall Incomplete 
recall
p
n 14 30
Data at the time of informed consent
GCS (mean ± SD) 15 ± 0 15 ± 0 > 0.99a
SOFA score (median (range)) 2 (1–5) 2.5 (0–9) 0.18b
Temperature, °C (mean ± SD) 37.0 ± 0.5 37.2 ± 0.7 0.21a
Glycemia, mmol/l (mean ± SD) 7 ± 2 7 ± 3 0.38a
Creatinin, μmol/l (mean ± SD) 80 ±± 25 105 ± 78 0.24a
Bilirubin, mmol/l (mean ± SD) 13 ± 6 15 ± 6 0.18a
Medications
24 hours before informed consent
Morphine, n (percentage) 2 (14) 11 (37) 0.17c
Benzodiazepines, n (percentage) 1 (7) 5 (17) 0.65c
Vasopressors, n (percentage) 0 (0) 0 (0)
24 hours after informed consent
Morphine, n (percentage) 8 (57) 18 (60) > 0.99c
Benzodiazepines, n (percentage) 1 (7) 3 (10) > 0.99c
'Attitude' of the patients
Read leaflet before consent, n (percentage) 11 (79) 17 (57) 0.20c
Asked at least one question before consent, n (percentage) 8 (57) 6 (20) 0.03c
Read or asked, n (percentage) 13 (93) 18 (60) 0.03c
Read and asked, n (percentage) 6 (43) 5 (17) 0.13c
GCS, Glasgow Coma Scale; SOFA, Sequential Organ Failure Assessment score. In the complete recall group, patients able to mention their 
clinical trial participation and the two clinical trial components; in the incomplete recall group, patients were unable to mention their clinical trial 
participation or one of the clinical trial components. aStudent's t test; bMann–Whitney U test;cFisher's exact test.Critical Care    Vol 10 No 6    Chenaud et al.
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However, during the past few years, legislation has tried to
enhance protection for incompetent patients. Barriers to the
inclusion of ICU patients in research studies have increased,
especially across Europe [2,26]. We fully support the idea that
oversight is necessary to ensure the uniform application of eth-
ical standards [11], but the most dependable safeguard for
the research subject is investigator understanding and respect
of the ethical requirements of clinical research.
Our study presents some limitations. First, the small number of
patients enrolled was dependent on the clinical trial. This
might have impeded the detection of other potential factors
that could influence the recall of the clinical trial. In addition,
the small clinical trial size precluded the possibility of a multi-
variate analysis. Second, we did not investigate the recall of
patients who had refused to participate in the clinical trial on
inflammation primarily because there was no consent to inves-
tigate. Perhaps the degree of recall might have been different
in patients who had refused participation. Third, we did not
assess patients' cognitive capacity. There is good evidence
that the cognitive capacity of ICU patients, or even sick
patients in general, is impaired [27,28]. However, spending
more time with patients to test their cognitive capacity, and
interacting with them for much longer than for a 'standard'
informed consent procedure, would have biased our results. It
is for this same reason that we did not measure the patients'
memory. Fourth, scores of severity of illness and laboratory val-
ues may suggest that patients with incomplete recall were
more ill than those with complete recall. Although not statisti-
cally significant, these results do not allow for the possibility
that the severity of the disease might act on recall. However,
the fundamental message remains that a poor rate of recall of
a clinical trial is present in ICU patients. Finally, as our patients
were presumed fully competent, the study faced the best pos-
sible situation in ICU patients. We are aware that these
patients do not represent the majority of ICU patients and our
results may therefore not be generalizable. However, it is rea-
Table 3
Value of 'asking one question' and 'reading the informative leaflet or asking one question' to recall the clinical trial
Parameter OR, complete 
versus incomplete 
recall
Sensitivity Specificity Positive predictive 
value
Negative 
predictive value
Likelihood ratio
Asked one 
question
5.3 (1.3–21) 0.57 (0.29–0.82) 0.80 (0.61–0.92) 0.57 (0.29–0.82) 0.80 (0.61–0.92) 2.86
Read leaflet or 
asked one 
question
8.7 (1.0–75) 0.93 (0.66–1.00) 0.40 (0.23–0.59) 0.42 (0.25–0.61) 0.92 (0.64–1.00) 1.55
OR, odds ratio. In the complete recall group, patients able to mention their study participation and the two clinical trial components; in the 
incomplete recall group, patients were unable to mention their clinical trial participation or one of the clinical trial components. Figures in 
parentheses are 95% confidence intervals.
Table 4
Patient characteristics, rate of recall and attitude of the patients during the informed consent procedure according to the two 
investigators.
Investigator 1 Investigator 2 p value
Age of the patients, mean (SD) 48 (22) 56 (20) 0.21
Sex of the patients, male/female 11/4 17/12 0.29
SAPS II of the patients 20 (9) 18 (10) 0.56
Patients with Complete recall, n (percentage) 3 (20) 11 (38) 0.38
Patients with recall of study participation, n (percentage) 10 (67) 25 (86) 0.14
Patients with recall of the study purpose, n (percentage) 4 (27) 16 (55) 0.07
Patients with recall of the study risk, n (percentage) 7(46) 14(48) 0.99
Attitude of the patients before consent, n (percentage)
Read leaflet 8 (53) 20 (69) 0.30
Asked at least one question 6 (40) 8 (28) 0.40
Read or asked 10 (67) 21 (72) 0.74
Read and asked 4 (27) 7 (24) 0.99Available online http://ccforum.com/content/10/6/R170
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sonable to speculate that the rate of recall may be even worse
in usual patients in the ICU.
Conclusion
To respect the principle of autonomy in the informed consent
procedure, patients should be able to decide freely without
any external pressure whether they agree to continue to partic-
ipate in a clinical trial at any time. In concordance with our pre-
vious paper, about 80% of ICU patients are able to recall their
clinical trial participation. However, as hypothesized, the rate
of recall of the clinical trial components is very low. We pre-
sume that it could be much lower than in patients informed
before being admitted to the ICU. Our results reinforce the
importance of viewing informed consent as a process and the
need for revisiting informed consent several times during an
ongoing clinical trial. We suggest that investigators, while the
research is conducted., repeatedly repeat clinical trial informa-
tion to the participants even after their ICU stay. We therefore
propose to reassess regularly whether continued participation
in a clinical trial is desired by the patient, as recommended pre-
viously [11]. Whether encouraging patients to read the inform-
ative leaflet and ask questions about the clinical trial improves
the informed consent procedure remains to be fully
investigated.
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